[go: up one dir, main page]

DK1572246T3 - Hidtil ukendte sammensætninger af magnetiske partikler overtrukket med gembisphosphonatderivater - Google Patents

Hidtil ukendte sammensætninger af magnetiske partikler overtrukket med gembisphosphonatderivater

Info

Publication number
DK1572246T3
DK1572246T3 DK03799680T DK03799680T DK1572246T3 DK 1572246 T3 DK1572246 T3 DK 1572246T3 DK 03799680 T DK03799680 T DK 03799680T DK 03799680 T DK03799680 T DK 03799680T DK 1572246 T3 DK1572246 T3 DK 1572246T3
Authority
DK
Denmark
Prior art keywords
magnetic particles
gembis
particles coated
novel compositions
phosphonate derivatives
Prior art date
Application number
DK03799680T
Other languages
English (en)
Inventor
Marc Port
Claire Corot
Isabelle Raynal
Olivier Rousseaux
Original Assignee
Guerbet Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guerbet Sa filed Critical Guerbet Sa
Application granted granted Critical
Publication of DK1572246T3 publication Critical patent/DK1572246T3/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1842—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a phosphate or a phosphonate, not being a phospholipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03799680T 2002-12-20 2003-12-19 Hidtil ukendte sammensætninger af magnetiske partikler overtrukket med gembisphosphonatderivater DK1572246T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0216410A FR2848850B1 (fr) 2002-12-20 2002-12-20 Nouvelles compositions de particules magnetiques recouvertes de derives gem-bisphosphonates.
PCT/FR2003/003855 WO2004058275A2 (fr) 2002-12-20 2003-12-19 Compositions de particules magnetiques recouvertes de derives gem-bisphosphonates

Publications (1)

Publication Number Publication Date
DK1572246T3 true DK1572246T3 (da) 2009-06-08

Family

ID=32406319

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03799680T DK1572246T3 (da) 2002-12-20 2003-12-19 Hidtil ukendte sammensætninger af magnetiske partikler overtrukket med gembisphosphonatderivater

Country Status (14)

Country Link
US (2) US7780953B2 (da)
EP (1) EP1572246B1 (da)
JP (1) JP4638738B2 (da)
CN (1) CN100358584C (da)
AT (1) ATE423575T1 (da)
AU (1) AU2003299388A1 (da)
BR (1) BR0316886A (da)
CA (1) CA2510531C (da)
DE (1) DE60326383D1 (da)
DK (1) DK1572246T3 (da)
ES (1) ES2321709T3 (da)
FR (1) FR2848850B1 (da)
PT (1) PT1572246E (da)
WO (1) WO2004058275A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263739B2 (en) * 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
AU2003232887A1 (en) * 2002-02-07 2003-09-02 The General Hospital Corporation STRUCTURE OF INTEGRIN AlphaV-Beta3 EXTRACELLULAR DOMAIN COMPLEXED WITH LIGAND
US20060239913A1 (en) * 2003-06-25 2006-10-26 Marc Port Peptide conjugate for magnetic resonance imaging
FR2856689A1 (fr) * 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
US8060179B1 (en) 2006-11-16 2011-11-15 Scientific Nanomedicine, Inc. Biomagnetic detection and treatment of Alzheimer's Disease
US8118754B1 (en) 2007-11-15 2012-02-21 Flynn Edward R Magnetic needle biopsy
US7510555B2 (en) * 2004-05-07 2009-03-31 Therm Med, Llc Enhanced systems and methods for RF-induced hyperthermia
US20070250139A1 (en) * 2004-05-07 2007-10-25 John Kanzius Enhanced systems and methods for RF-induced hyperthermia II
US7627381B2 (en) * 2004-05-07 2009-12-01 Therm Med, Llc Systems and methods for combined RF-induced hyperthermia and radioimmunotherapy
US20050251233A1 (en) * 2004-05-07 2005-11-10 John Kanzius System and method for RF-induced hyperthermia
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US9964469B2 (en) 2005-02-28 2018-05-08 Imagion Biosystems, Inc. Magnetic needle separation and optical monitoring
US7598199B2 (en) * 2005-05-10 2009-10-06 Massachusetts Institute Of Technology Catalytic nanoparticles for nerve-agent destruction
EP1940841B9 (fr) 2005-10-07 2017-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
WO2007072982A1 (en) * 2005-12-20 2007-06-28 Fujifilm Corporation Protein nanoparticles and the use of the same
FR2904784B1 (fr) * 2006-08-10 2010-09-03 Surfactis Technologies Procede de recouvrement de surfaces metalliques et minerales par de monocouches autoassemblees de composes bisphosphoniques et leurs utilisations
US8447379B2 (en) 2006-11-16 2013-05-21 Senior Scientific, LLC Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof
FR2913886B1 (fr) * 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
FR2914303A1 (fr) 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
FR2914304B1 (fr) 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
FR2921838A1 (fr) * 2007-10-05 2009-04-10 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile
FR2921837B1 (fr) * 2007-10-05 2015-07-31 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice organique couplee a des ligands de ciblage
JP2011515535A (ja) * 2008-03-17 2011-05-19 キャボット コーポレイション リン酸塩遊離が低減した改質顔料、ならびにそれからの分散体およびインクジェットインク組成物
US8057976B2 (en) * 2008-08-21 2011-11-15 Empire Technology Development Llc Method for producing toner
US9205155B2 (en) * 2009-10-30 2015-12-08 General Electric Company Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents
US10194825B2 (en) 2009-11-06 2019-02-05 Imagion Biosystems Inc. Methods and apparatuses for the localization and treatment of disease such as cancer
CN102695473B (zh) 2009-11-06 2015-09-23 纳米医学科学公司 使用靶向纳米粒子及其磁特性的细胞如癌细胞和其他生物物质的检测、测量和成像
US9217085B2 (en) 2010-07-21 2015-12-22 Solvay (China) Co;. Ltd Method of coating an inorganic substrate with a stable organic layer
KR101805873B1 (ko) 2011-08-03 2018-01-10 한화케미칼 주식회사 단당류 인산 또는 그 유도체로 표면이 개질된 친수성 나노입자, 그의 콜로이드 용액 및 그 용도
IT1401882B1 (it) 2010-10-01 2013-08-28 Rosa De Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.
FR2968562B1 (fr) 2010-12-14 2013-01-11 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de muc5ac
US8889103B2 (en) 2010-12-15 2014-11-18 General Electric Company Diagnostic agent composition and associated methods thereof
RU2013125324A (ru) * 2010-12-15 2015-01-20 Дженерал Электрик Компани Композиция наночастиц и связанные с ней способы
US8895068B2 (en) 2010-12-15 2014-11-25 General Electric Company Nanoparticle composition and associated methods thereof
EP2572736A1 (en) * 2011-09-23 2013-03-27 Spago Imaging AB Nanostructures comprising manganese
FR2990433A1 (fr) * 2012-05-10 2013-11-15 Surfactis Technologies Compositions catanioniques de recouvrement de surface par des molecules phosphoniques et amines
CN105524492A (zh) * 2016-01-12 2016-04-27 四川大学 一种简易低成本的磁性微粒表面活性基团引入方法
WO2018113663A1 (en) * 2016-12-19 2018-06-28 The Chinese University Of Hong Kong Injectable hydrogels that promote mineralization and afford sustained release of bioactive ions
CN111840547B (zh) * 2020-06-15 2023-04-28 山西振东泰盛制药有限公司 注射用培美曲塞磁性自组装纳米复合颗粒制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440646A (en) * 1965-08-24 1984-04-03 Plains Chemical Development Co. Chelation
GB1435295A (en) * 1973-11-19 1976-05-12 Research Corp Bone seeking technetium-99m complex
US4120890A (en) * 1976-01-21 1978-10-17 Henkel Kommanditgesellschaft Auf Aktien Diphosphonoalkane carboxylic acids, process of preparation and methods of use
FR2461521A1 (fr) * 1979-07-20 1981-02-06 Anvar Fluides magnetiques, notamment ferrofluides, et procede pour leur obtention
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ATE191086T1 (de) * 1994-07-27 2000-04-15 Pilgrimm Herbert Superparamagnetische teilchen, verfahren zur herstellung und deren verwendung
JPH08268987A (ja) * 1995-02-24 1996-10-15 Bristol Myers Squibb Co テトラリニル−，及びインダニル−エチルアミド誘導体
FR2736197B1 (fr) * 1995-06-29 1997-09-12 Univ Paris Curie Nanoparticules magnetiques couplees a de l'annexine et leur utilisation
EP1062515B1 (en) * 1998-02-12 2009-11-25 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO2001037721A2 (en) * 1999-11-22 2001-05-31 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
DE10016559A1 (de) * 2000-04-03 2001-10-18 Eucro Europe Contract Res Gmbh System für den Transport von Aktivstoffen in einem biologischen System
US6517814B2 (en) * 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
US20020122806A1 (en) * 2001-03-05 2002-09-05 Chinnaiyan Arul M. Compositions and methods for in situ and in vivo imaging of cells and tissues

Also Published As

Publication number Publication date
BR0316886A (pt) 2005-10-25
WO2004058275A2 (fr) 2004-07-15
CN1744920A (zh) 2006-03-08
CA2510531C (fr) 2012-09-04
AU2003299388A8 (en) 2004-07-22
CA2510531A1 (fr) 2004-07-15
WO2004058275A3 (fr) 2004-12-09
FR2848850A1 (fr) 2004-06-25
EP1572246B1 (fr) 2009-02-25
US7780953B2 (en) 2010-08-24
US20040253181A1 (en) 2004-12-16
CN100358584C (zh) 2008-01-02
US20100297025A1 (en) 2010-11-25
AU2003299388A1 (en) 2004-07-22
EP1572246A2 (fr) 2005-09-14
DE60326383D1 (de) 2009-04-09
JP2006513198A (ja) 2006-04-20
PT1572246E (pt) 2009-05-22
ATE423575T1 (de) 2009-03-15
ES2321709T3 (es) 2009-06-10
JP4638738B2 (ja) 2011-02-23
FR2848850B1 (fr) 2005-06-24

Similar Documents

Publication Publication Date Title
DK1572246T3 (da) Hidtil ukendte sammensætninger af magnetiske partikler overtrukket med gembisphosphonatderivater
AU3599801A (en) Reagents for the quantitation of active oxygen
MXPA04006581A (es) Derivados de sulfonato y su empleo como acidos latentes.
PH12009501118A1 (en) Chemical compounds
BR0108745A (pt) Revestimentos de barreira tendo bis-silanos
DE60032780D1 (de) Tetrahydroquinolin-derivate
AR057914A1 (es) Compuestos organicos de azufre y su uso
ATE342896T1 (de) Fluoreszierende proben zur quantitativen bestimmung von zink
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
MXPA04005802A (es) Derivados sustituidos de fenilo.
WO2005042444A3 (ja) 白金錯体及び発光素子
WO2005042444A1 (ja) 白金錯体及び発光素子
MXPA04004347A (es) Nuevos fotoindicadores difuncionales.
ATE352554T1 (de) Neue picolinaminderivate und deren verwendung als fungizide
AU7824900A (en) Compounds and methods for inhibiting mrp1
BR0318125A (pt) Derivados de benzeno trìmeros macrociclicamente substituìdos
EP1398306A3 (en) A (1'R, 2'S, 5'R)-3-l-Menthoxyalkan-1-ol cooling sensate
EP1325923A4 (en) CEPHEM COMPOUNDS AND ESBL DETERGENT REAGENTS CONTAINING THEM
MXPA02007973A (es) Compuestos de aminoacidos y su uso como inhibidores de nep, ace y ece.
BRPI0206922B8 (pt) composto de fragrância, composição de fragrância contendo o mesmo, e método para preparação de um composto de fragrância
DE50203353D1 (de) 1,3-dihydroxybenzol-derivate und diese verbindungen enthaltende färbemittel
ATE254099T1 (de) Trimethyldecen-verbindungen
BR9902096A (pt) Pitazóis.
BG103705A (en) Phenoxyacetic acid derivatives and their application as herbicides
DK1592303T3 (da) Behandling af slam eller opslæmninger